Mark Fletcher, MD
Neurology · Tupelo, MSNPI 1225021371
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by Sanofi at 50.6% of the total. Reporting peaked in 2019 at $20,380 and has fallen 84.1% since, to $3,245 in 2025.
Across 1,056 payments — averaging $38.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$21K
- AbbVie$5K
- Novartis$1K
- AstraZeneca$989
- Teva Pharmaceuticals USA, Inc.$859
- SK Life Science, Inc.$790
- plus $11K from 47 others
What the payments were for
- Speaking & faculty fees$17,22442%
- Travel & lodging$4,19210%
- Food & beverage$19,22547%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUBAGIO$19,683
- BOTOX$1,382
- GABLOFEN$468
- VNS Therapy$135
- Rystiggo$129
- Epidiolex$125
- MITIGO$117
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$113
- VYVGART$104
- NURTEC ODT$103
How this compares
$40,677 in reported general payments places this provider in the 85th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 33 | $236,670 |
| IngrezzaValbenazine Tosylate | 13 | $109,823 |
| WakixPitolisant Hcl | 12 | $91,459 |
| NuplazidPimavanserin Tartrate | 22 | $74,812 |
| NuedextaDextromethorphan Hbr/Quinidine | 44 | $70,752 |
| Nurtec OdtRimegepant Sulfate | 38 | $46,674 |
| KeppraLevetiracetam | 17 | $33,455 |
| Emgality SyringeGalcanezumab-Gnlm | 19 | $28,636 |
| UbrelvyUbrogepant | 22 | $24,117 |
| RytaryCarbidopa/Levodopa | 18 | $22,654 |
| Aimovig AutoinjectorErenumab-Aooe | 26 | $19,273 |
| EliquisApixaban | 22 | $17,576 |
| BriviactBrivaracetam | 12 | $16,965 |
| XcopriCenobamate | 17 | $16,567 |
| LamictalLamotrigine | 24 | $15,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $300 | $109,82313 claims |
| Harmony Biosciences LLCWakix | $423 | $91,45912 claims |
| Acadia Pharmaceuticals IncNuplazid | $555 | $74,81222 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $313 | $70,75244 claims |
| PfizerNurtec Odt, Eliquis, Dilantin | $641 | $66,02772 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $304 | $26,59779 claims |
| AbbVieUbrelvy | $5,284 | $24,11722 claims |
| UCB, Inc.Briviact | $531 | $16,96512 claims |
| SK Life Science, Inc.Xcopri | $790 | $16,56717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 neurology providers in Mississippi.
Other neurology in Tupelo
- Stephen LandyTupelo$1.9M
- Justin GraffTupelo$85K
- Samuel NewellTupelo$10K
- Donna HarringtonTupelo$6K
- William OakesTupelo$3K
- Ali AhmadTupelo$2K
- Esther FischerTupelo$2K
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Ronald SchwartzHattiesburg$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.